ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "11565ac6-87f1-45e2-8efe-15e63422c0ea"}, "_deposit": {"created_by": 14, "id": "2503", "owners": [14], "pid": {"revision_id": 0, "type": "depid", "value": "2503"}, "status": "published"}, "_oai": {"id": "oai:dmu.repo.nii.ac.jp:00002503", "sets": ["191"]}, "author_link": ["371", "10892", "10895", "6909", "6407", "10894", "10893", "9"], "item_10001_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2021-03-25", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "42", "bibliographicPageStart": "33", "bibliographicVolumeNumber": "48", "bibliographic_titles": [{"bibliographic_title": "Dokkyo Journal of Medical Sciences"}]}]}, "item_10001_description_35": {"attribute_name": "要旨(英)", "attribute_value_mlt": [{"subitem_description": "Hyperkalemia is known as a major adverse effect of nafamostat, a serine protease inhibitor, and its mechanism is thought as inhibition of an amiloride-sensitive Na+ channel. Kallikrein is a serine protease and can activate the amiloride-sensitive Na+ channel. The study examined whether urine potassium excretion and kallikrein activity decrease in a nafamostat-induced hyperkalemia model. First, rats were administered nafamostat(1.2 mg/kg/h)or 5% glucose by a continuous intravenous infusion(c.i.)under general anesthesia, and urine and blood samples were collected every 15 minutes from 30 minutes before until 90 minutes after drug administration. Next, nafamostat(0.13, 0.4, 1.2 mg/kg/h c.i.)or 5% glucose was co-administered by a low-dose amiloride(3.33 µg/kg i.v. followed by 12 µg/kg/h c.i.)in the same time course. Changes in Δ serum potassium concentrations, a difference from the baseline, and those in urine potassium excretion and kallikrein activity, and their means of the last three points were evaluated. Statistical analyses were conducted by a repeated measure ANOVA(α=0.05, one-tail test). In results, increasing and decreasing trends were observed regarding with the changes in Δ potassium and potassium excretion, and their corresponding means of the last three points, respectively, in the nafamostat group compared with control group. In the next experiment, changes in the Δ serum potassium concentrations and those in urine potassium excretion, and their corresponding means of the last three points significantly increased and decreased, respectively, in the nafamostat group compared with the control group. A significant decrease in urine kallikrein activity was shown by the maximum dose of nafamostat regarding with the means of the last three points compared to the control. In conclusions, nafamostat induced renal hyperkalemia in vivo via inhibition of the amiloride-sensitive Na+ channel, which was associated with inhibition of urine kallikrein activity.", "subitem_description_type": "Other"}]}, "item_10001_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "獨協医学会"}]}, "item_10001_source_id_11": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AA00629581", "subitem_source_identifier_type": "NCID"}]}, "item_10001_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "03855023", "subitem_source_identifier_type": "ISSN"}]}, "item_10001_text_25": {"attribute_name": "著者所属(英)", "attribute_value_mlt": [{"subitem_text_language": "en", "subitem_text_value": "Department of Anesthesiology, Dokkyo Medical University School of Medicine, Tochigi 321-0293, Japan"}, {"subitem_text_language": "en", "subitem_text_value": "Research Center for Laboratory Animals, Dokkyo Medical University School of Medicine"}, {"subitem_text_language": "en", "subitem_text_value": "Research Center for Laboratory Animals, Dokkyo Medical University School of Medicine"}, {"subitem_text_language": "en", "subitem_text_value": "Department of Pharmacology and Toxicology, Dokkyo Medical University School of Medicine"}, {"subitem_text_language": "en", "subitem_text_value": "Department of Anesthesiology, Dokkyo Medical University School of Medicine, Tochigi 321-0293, Japan"}, {"subitem_text_language": "en", "subitem_text_value": "Department of Anesthesiology, Dokkyo Medical University School of Medicine, Tochigi 321-0293, Japan"}, {"subitem_text_language": "en", "subitem_text_value": "Department of Anesthesiology, Dokkyo Medical University School of Medicine, Tochigi 321-0293, Japan"}, {"subitem_text_language": "en", "subitem_text_value": "Department of Pharmacology and Toxicology, Dokkyo Medical University School of Medicine"}]}, "item_10001_text_33": {"attribute_name": "記事種別", "attribute_value_mlt": [{"subitem_text_value": "Original"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Yamada, Teppei", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "10892", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kaneko, Hiromichi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "10893", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Inose, Chihiro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "10894", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tanaka-Nakadate, Sawako", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "6407", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hanawa, Hiroki", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "10895", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hamaguchi, Shinsuke", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "371", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamaguchi, Shigeki", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "9", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fujita, Tomoe", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "6909", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2021-05-20"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "DJMS-48-1-5.pdf", "filesize": [{"value": "517.3 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 517299.99999999994, "url": {"label": "DJMS-48-1-Yamada-本文", "url": "https://dmu.repo.nii.ac.jp/record/2503/files/DJMS-48-1-5.pdf"}, "version_id": "cf257bf0-a9fe-4d04-bdc1-04f2f1b271be"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Tissue kallikrein", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Nafamostat", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Amiloride", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Renal hyperkalemia", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Rat", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Effect of In-vivo Administration of Nafamostat on the Onset of Renal Hyperkalemia and Association of Urine Kallikrein in Rats", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Effect of In-vivo Administration of Nafamostat on the Onset of Renal Hyperkalemia and Association of Urine Kallikrein in Rats"}]}, "item_type_id": "10001", "owner": "14", "path": ["191"], "permalink_uri": "https://dmu.repo.nii.ac.jp/records/2503", "pubdate": {"attribute_name": "公開日", "attribute_value": "2021-05-21"}, "publish_date": "2021-05-21", "publish_status": "0", "recid": "2503", "relation": {}, "relation_version_is_last": true, "title": ["Effect of In-vivo Administration of Nafamostat on the Onset of Renal Hyperkalemia and Association of Urine Kallikrein in Rats"], "weko_shared_id": -1}
  1. Dokkyo Journal of Medical Sciences
  2. 48(1) 2021

Effect of In-vivo Administration of Nafamostat on the Onset of Renal Hyperkalemia and Association of Urine Kallikrein in Rats

https://dmu.repo.nii.ac.jp/records/2503
https://dmu.repo.nii.ac.jp/records/2503
66afc127-fabf-4f23-8b90-da488d952204
名前 / ファイル ライセンス アクション
DJMS-48-1-5.pdf DJMS-48-1-Yamada-本文 (517.3 kB)
Item type 学術雑誌論文 / Journal Article(1)
タイトル
タイトル Effect of In-vivo Administration of Nafamostat on the Onset of Renal Hyperkalemia and Association of Urine Kallikrein in Rats
言語
言語 eng
キーワード
言語 en
主題Scheme Other
主題 Tissue kallikrein
キーワード
言語 en
主題Scheme Other
主題 Nafamostat
キーワード
言語 en
主題Scheme Other
主題 Amiloride
キーワード
言語 en
主題Scheme Other
主題 Renal hyperkalemia
キーワード
言語 en
主題Scheme Other
主題 Rat
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_6501
資源タイプ journal article
著者 Yamada, Teppei

× Yamada, Teppei

WEKO 10892

en Yamada, Teppei

Search repository
Kaneko, Hiromichi

× Kaneko, Hiromichi

WEKO 10893

en Kaneko, Hiromichi

Search repository
Inose, Chihiro

× Inose, Chihiro

WEKO 10894

en Inose, Chihiro

Search repository
Tanaka-Nakadate, Sawako

× Tanaka-Nakadate, Sawako

WEKO 6407

en Tanaka-Nakadate, Sawako

Search repository
Hanawa, Hiroki

× Hanawa, Hiroki

WEKO 10895

en Hanawa, Hiroki

Search repository
Hamaguchi, Shinsuke

× Hamaguchi, Shinsuke

WEKO 371

en Hamaguchi, Shinsuke

Search repository
Yamaguchi, Shigeki

× Yamaguchi, Shigeki

WEKO 9

en Yamaguchi, Shigeki

Search repository
Fujita, Tomoe

× Fujita, Tomoe

WEKO 6909

en Fujita, Tomoe

Search repository
著者所属(英)
en
Department of Anesthesiology, Dokkyo Medical University School of Medicine, Tochigi 321-0293, Japan
著者所属(英)
en
Research Center for Laboratory Animals, Dokkyo Medical University School of Medicine
著者所属(英)
en
Research Center for Laboratory Animals, Dokkyo Medical University School of Medicine
著者所属(英)
en
Department of Pharmacology and Toxicology, Dokkyo Medical University School of Medicine
著者所属(英)
en
Department of Anesthesiology, Dokkyo Medical University School of Medicine, Tochigi 321-0293, Japan
著者所属(英)
en
Department of Anesthesiology, Dokkyo Medical University School of Medicine, Tochigi 321-0293, Japan
著者所属(英)
en
Department of Anesthesiology, Dokkyo Medical University School of Medicine, Tochigi 321-0293, Japan
著者所属(英)
en
Department of Pharmacology and Toxicology, Dokkyo Medical University School of Medicine
書誌情報 Dokkyo Journal of Medical Sciences

巻 48, 号 1, p. 33-42, 発行日 2021-03-25
要旨(英)
内容記述タイプ Other
内容記述 Hyperkalemia is known as a major adverse effect of nafamostat, a serine protease inhibitor, and its mechanism is thought as inhibition of an amiloride-sensitive Na+ channel. Kallikrein is a serine protease and can activate the amiloride-sensitive Na+ channel. The study examined whether urine potassium excretion and kallikrein activity decrease in a nafamostat-induced hyperkalemia model. First, rats were administered nafamostat(1.2 mg/kg/h)or 5% glucose by a continuous intravenous infusion(c.i.)under general anesthesia, and urine and blood samples were collected every 15 minutes from 30 minutes before until 90 minutes after drug administration. Next, nafamostat(0.13, 0.4, 1.2 mg/kg/h c.i.)or 5% glucose was co-administered by a low-dose amiloride(3.33 µg/kg i.v. followed by 12 µg/kg/h c.i.)in the same time course. Changes in Δ serum potassium concentrations, a difference from the baseline, and those in urine potassium excretion and kallikrein activity, and their means of the last three points were evaluated. Statistical analyses were conducted by a repeated measure ANOVA(α=0.05, one-tail test). In results, increasing and decreasing trends were observed regarding with the changes in Δ potassium and potassium excretion, and their corresponding means of the last three points, respectively, in the nafamostat group compared with control group. In the next experiment, changes in the Δ serum potassium concentrations and those in urine potassium excretion, and their corresponding means of the last three points significantly increased and decreased, respectively, in the nafamostat group compared with the control group. A significant decrease in urine kallikrein activity was shown by the maximum dose of nafamostat regarding with the means of the last three points compared to the control. In conclusions, nafamostat induced renal hyperkalemia in vivo via inhibition of the amiloride-sensitive Na+ channel, which was associated with inhibition of urine kallikrein activity.
記事種別
Original
出版者
出版者 獨協医学会
ISSN
収録物識別子タイプ ISSN
収録物識別子 03855023
書誌レコードID
収録物識別子タイプ NCID
収録物識別子 AA00629581
戻る
0
views
See details
Views

Versions

Ver.1 2023-06-20 14:50:36.323121
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3